CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

Showing 5 of 5 entries

View as:

Phase: N/A Priority: Normal

NCT ID: NCT03311555 Org: User:

Start: 03/28/18 End: 12/22/22 Due: 12/22/23

Phase: N/A Priority: Normal

NCT ID: NCT01513733 Org: User:

Start: 01/31/12 End: 06/30/16 Due: 06/30/17

Phase: N/A Priority: Normal

NCT ID: NCT03179410 Org: User:

Start: 02/01/18 End: 12/18/20 Due: 12/18/21

Phase: N/A Priority: Normal

NCT ID: NCT04709276 Org: User:

Start: 06/07/21 End: 06/30/28 Due: 06/30/29

Phase: N/A Priority: Normal

NCT ID: NCT01385293 Org: User:

Start: 08/31/11 End: 02/29/16 Due: 02/28/17

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)	NCT03311555	Andrew J. Armstrong, MD	user2@example.com	None	2018-03-28	2022-12-22	2023-12-22	-	-	2025-07-14
The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer	NCT01513733	Andrew J. Armstrong, MD	user2@example.com	None	2012-01-31	2016-06-30	2017-06-30	-	-	2025-07-14
PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer	NCT03179410	Andrew J. Armstrong, MD	user2@example.com	None	2018-02-01	2020-12-18	2021-12-18	-	-	2025-07-14
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer	NCT04709276	Andrew J. Armstrong, MD	user2@example.com	None	2021-06-07	2028-06-30	2029-06-30	-	-	2025-07-14
BKM120 in Metastatic Castration-resistant Prostate Cancer	NCT01385293	Andrew J. Armstrong, MD	user2@example.com	None	2011-08-31	2016-02-29	2017-02-28	-	-	2025-07-14